Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma

Pathology and Oncology Research

Volumn 8, Issue 3, 2002, Pages 183-187

  Bánfalvi, Teodóra ^a   Boldizsár, Mariann ^a   Gergye, Maria ^a   Gilde, Katalin ^a   Kremmer, Tibor ^a   Ottó, Szabolcs ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

5 S Cysteinyldopa; LDH; Melanoma; Progression; S 100B

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CALCIUM BINDING PROTEIN; CARMUSTINE; CISPLATIN; CYSTEINYLDOPA; CYTOPLASM PROTEIN; DACARBAZINE; LACTATE DEHYDROGENASE; LOMUSTINE; MELANIN; PHEOMELANIN; PROTEIN PRECURSOR; PROTEIN S100B; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ADULT; AGED; ARTICLE; ASSAY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MOLECULAR WEIGHT; PROGNOSIS; PROTEIN BLOOD LEVEL; RELIABILITY; ULTRAVIOLET RADIATION; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CYSTEINYLDOPA; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036446555     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032392     Document Type: Article

References (30)

1. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on cancer staging system cutaneous melanoma. Cancer 88: 1484-1491, 2000
2. Bánfalvi T, Glide K, Boldizsár M. et al: Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res 5: 218-223, 1999
3. Bánfalvi T. Gilde K. Boldizsár M, et al: Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 30: 900-904, 2000
4. Benathan M. Labidi F: Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res 6: 183-189, 1996
5. Berking C, Schlüpen E. Schrader A, et al: Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminometric assay for S-100. Arch Dermatol Res 291: 479-484, 1999
6. Buer J, Probst M, Franzke A et al: Elevated serum levels of S-100 and survival in metastatic malignant melanoma. Br J Cancer 75: 1373-1376, 1997
7. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of new staging system. J Clin Oncol 15: 1039-1051, 1997
8. Clark WH Jr, From L, Bernardino EA, Mihm MC: The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29: 705-726, 1991
9. Deichmann M, Benner A, Bock Mjackel A, et al: S-100 beta, melanoma inhibiting activity and lactate dehydrogenase discriminate progressive from nonprogressive AJCC Stage IV melanoma. J Clin Oncol 17: 1891-1896, 1999
10. Deichmann M, Benner A, Kuner N et al: Are responses to therapy of metastatized melanoma reflected by decreasing serum values of S-100 beta or MIA? Melanoma Res. 11: 291-296, 2001
11. Djukanovic D, Hofmann U, Sucker A, et al: Comparison of S-100 protein and MIA protein as serum markers in malignant melanoma. Anticancer Res 20: 2203-2207, 2000
12. Franzke A, Probst-kepper M, Buer J, et al: Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78: 40-45, 1998
13. Guo HB, Stoffel-Wagner B, Bierwirth T, et al: Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer 31A: 1898-1902, 1995
14. Hansson C, Edholm L, Agrup G, et al: The quantitative determination of 5-S-cysteinyl-dopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high performance liquid chromatography. Clin Chim Acta 88: 419-421, 1978
15. Hasegawa M, Takata M, Hatta N, Wakamatsu K, et al: Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7: 243-251, 1997
16. Hauschild A: The use of serological tumor markers for malignant melanoma. Onkologie 20: 462-465, 1997
17. Hauschild A, Michaelsen J, Brenner W, et al: Prognostic significance of serum S-100B detection compared to routin blood parameters in advanced metastatic melanoma patients, Melanoma Res 9: 155-161, 1999
18. Horikoshi T, Ito Sh, Wakamatsu K, et al: Evaluation of melaninrelated metabolites as markers of melanoma progression. Cancer 73: 629-636, 1994.
19. Karnell R, von Schoultz E, Hansson LO, et al.: S 100 B protein, 5-S-cysteinyldopa and 6-hydroxy-5-metoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 7: 393-399, 1997
20. Karnell R. Kagedal B., Lindholm C, et al: The value of cysteinyldopa in the follow up of disseminated malignant melanoma. Melanoma Res 10: 363-369, 2000
21. Krahn G, Kaskel P, Sander S, et al: S-100 beta is a more reliable tumor marker in peripherial blood of patients with newly occurred melanoma metastases comparing to MIA, albumin and lactat dehydrogenase. Anticancer Res 21: 311-1316, 2001
22. Martenson ED, Hansson LO, Nilsson B, et al.: Serum S-100b protein as prognostic marker in malignant cutaneuos melanoma. J Clin Oncol 19: 824-831, 2001
23. Meyerhoffer S, Lindberg Z, Hager A, et al: Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta Derm Venereol 78: 31-35, 1998
24. Sasaki Y, Shimizu H, Naka W, et al: Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: Ten years experience of 50 patients. Acta Derm Venerol 77: 379-381, 1998
25. Seregeni E, Massaron S, Martinetti A, et al: S-100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5: 601-604, 1998
26. Schmitz C, Brenner W, Henze E, et al: Comparative study on the clinical use of protein S-100 B and MIA in melanoma patients. Anticancer Res 20: 5059-5063, 2000
27. Schoultz ES, Diepgen TL, von den Dresch P: Clinical prognostic relevance of serum S-100b protein in malignant melanoma. Br J Dermatol 38: 426-430, 1998
28. Wakamatsu K, Ito S: Seasonal variations in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyl acid in healthy Japanese. Pigment Cell Res 8: 132-134, 1995
29. Wibe E, Hannisdal E, Paus E, Aamdal S: Neuron-specific enolase as prognostic factor in metastatic melanoma. Eur J Cancer 28: 1692-1695, 1992
30. Wimmer I, Meyer CJ, Seifert B, et al.: Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy. Cancer Res 57: 5073-5076, 1997